Status of subjects undergoing autologous SCT for AIDS lymphoma.a
| UPN . | Diagnosis . | HAART . | Prior Chemotherapy . | Statusb . |
|---|---|---|---|---|
| Abbreviations: A, abacavir; CR, complete response (remission); E, efavirenz; I, indinavir; Ifos/VP16, ifosfamide/etoposide; L, lamivudine; Nf, nelfinavir; Nv, nevirapine; R, ritonavir; RTX, Rituxan; Sa, saquinavir; S, stavudine; CHOP, cyclophosphamide, Adriamycin, vincristine, prednisone; ESHAP, etoposide, cytarabine, cisplatinum, prednisone; BOSE, bleomycin, oncovin, streptozocin, etoposide; ABVD, Adriamycin, bleomycin, vincristine/vinblastine, dacarbazine; M-BACOD, methotrexate, bleomycin, Adriamycin, cyclophosphamide, vincristine, dexamethosone; POG8617, cyclophosphamide, Adriamycin, cytarabine; POG9517, same plus methotrexate, Ifos, VP16; POG9317, Ifos, VP16, methotrexate, cytarabine; FTBI, fractionated total body irradiation | ||||
| a. All subjects, except UPN410, received autologous stem cell transplant after cyclophosphamide, BCNU, VP16 (CBV), UPN410 received FTBI, cyclophosphamide, VP16; | ||||
| b. Status at June 15, 2001 | ||||
| 202 | NHL | Nf, L, S | CHOP | CR; 30 mo |
| 203 | HD | I, L, S | CHOP, Ifos/VP16, ESHAP | CR; 23 mo |
| 204 | NHL | Nf, L, S | CHOP, ESHAP | Relapse/death 4 mo |
| 208 | NHL | Nf, Nv, S | CHOP, ESHAP | CR; 23 mo |
| 209 | HD | I, L | BOSE, ABVD, ESHAP | CR; 18 mo |
| 400 | NHL | Nf, Nv, L | POG-8617, -9517, and –9317 | Relapse/death 4 mo |
| 405 | NHL | I, L, S | CHOP, ESHAP, RTX | CR; 36 mo |
| 406 | NHL | R, S, Nv, Sa | CHOP, Ifos/VP16, RTX, ESHAP | CR; 30 mo |
| 407 | NHL | E, L, S | CHOP, | CR; 18 mo |
| 408 | NHL | R, S, Sa | M-BACOD, ESHAP | CR; 10 mo |
| 409 | NHL | L, A, Nf | CHOP, ESHAP | Death day 22 |
| 410 | NHL | L, E, Sa | CHOP, ESHAP | CR; 7 mo |
| UPN . | Diagnosis . | HAART . | Prior Chemotherapy . | Statusb . |
|---|---|---|---|---|
| Abbreviations: A, abacavir; CR, complete response (remission); E, efavirenz; I, indinavir; Ifos/VP16, ifosfamide/etoposide; L, lamivudine; Nf, nelfinavir; Nv, nevirapine; R, ritonavir; RTX, Rituxan; Sa, saquinavir; S, stavudine; CHOP, cyclophosphamide, Adriamycin, vincristine, prednisone; ESHAP, etoposide, cytarabine, cisplatinum, prednisone; BOSE, bleomycin, oncovin, streptozocin, etoposide; ABVD, Adriamycin, bleomycin, vincristine/vinblastine, dacarbazine; M-BACOD, methotrexate, bleomycin, Adriamycin, cyclophosphamide, vincristine, dexamethosone; POG8617, cyclophosphamide, Adriamycin, cytarabine; POG9517, same plus methotrexate, Ifos, VP16; POG9317, Ifos, VP16, methotrexate, cytarabine; FTBI, fractionated total body irradiation | ||||
| a. All subjects, except UPN410, received autologous stem cell transplant after cyclophosphamide, BCNU, VP16 (CBV), UPN410 received FTBI, cyclophosphamide, VP16; | ||||
| b. Status at June 15, 2001 | ||||
| 202 | NHL | Nf, L, S | CHOP | CR; 30 mo |
| 203 | HD | I, L, S | CHOP, Ifos/VP16, ESHAP | CR; 23 mo |
| 204 | NHL | Nf, L, S | CHOP, ESHAP | Relapse/death 4 mo |
| 208 | NHL | Nf, Nv, S | CHOP, ESHAP | CR; 23 mo |
| 209 | HD | I, L | BOSE, ABVD, ESHAP | CR; 18 mo |
| 400 | NHL | Nf, Nv, L | POG-8617, -9517, and –9317 | Relapse/death 4 mo |
| 405 | NHL | I, L, S | CHOP, ESHAP, RTX | CR; 36 mo |
| 406 | NHL | R, S, Nv, Sa | CHOP, Ifos/VP16, RTX, ESHAP | CR; 30 mo |
| 407 | NHL | E, L, S | CHOP, | CR; 18 mo |
| 408 | NHL | R, S, Sa | M-BACOD, ESHAP | CR; 10 mo |
| 409 | NHL | L, A, Nf | CHOP, ESHAP | Death day 22 |
| 410 | NHL | L, E, Sa | CHOP, ESHAP | CR; 7 mo |